Autopsy report · NCT02276170

Pharmacology of Aminophylline for Acute Kidney Injury in Neonates

“insufficient rate of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 10 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Sponsor

Stanford University

Sponsor type

University, hospital or other

Conditions

Acute Kidney Injury

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
  “insufficient accrual rate” (98% match in meaning)
• Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer
  “Accrual rate was too low” (88% match in meaning)
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
  “Poor accrual rate” (88% match in meaning)
• OD-PHOENIX in Talus Osteochondral Lesion
  “Low accrual rate” (87% match in meaning)
• sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer
  “Insufficient accrual” (83% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.